Premium
Transfusion‐associated graft‐versus‐host disease in fludarabine‐treated B‐chronic lymphocytic leukaemia
Author(s) -
Maung Z. T.,
Wood A. C.,
Jackson G. H.,
Turner G. E.,
Appleton A. L.,
Hamilton P. J.
Publication year - 1994
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1994.tb05093.x
Subject(s) - fludarabine , medicine , chronic lymphocytic leukemia , complication , purine analogue , graft versus host disease , immunology , hematology , gastroenterology , chemotherapy , leukemia , disease , purine , cyclophosphamide , enzyme , biochemistry , chemistry
Summary. Transfusion‐associated graft‐versus‐host disease (TA‐GVHD) is a rare but serious complication of blood component therapy in patients with haematological malignancies. B‐chronic lymphocytic leukaemia (B‐CLL), however, has rarely been associated with TA‐GVHD. We report three patients with advanced B‐CLL who developed TA‐GVHD. All these had been treated with fludarabine. Suppression of T cells by fludarabine may have contributed to an increased susceptibility to TA‐GVHD. The use of irradiated blood products to prevent this complication should be considered for patients with advanced B‐CLL treated with fludarabine or other purine analogues.